Ruggero De Maria, M.D.

PERSONAL DETAILS

Date of birth: 12/21/1964
Place of birth Rome

Main positions: *President,* Alliance Against Cancer (ACC), Italy
President, Italian Institute for Genomic Medicine, Turin, Italy
Director, Institute of General Pathology, Catholic University, Rome

Address: Largo F. Vito, 1
00168, Rome, IT
Tel. +39 063015-4914/6710
Fax: +39 063386446
Email : ruggerodemaria@gmail.com

EDUCATION

1989 MD (honors), University of Catania, Italy.
1989 License to practice Medicine.
1994 Specialty in Endocrinology (honors), University of Palermo, Italy.

RESEARCH AND PROFESSIONAL EXPERIENCE

2016-present *Full Professor of Pathology,* Catholic University*, Rome*, Italy
2016-present *President*, Human Genetics Foundation/Italian Institute for Genomic Medicine, Turin, Italy
2013-present *President,* Alliance Against Cancer (ACC), Italy.
2011-2015 *Director,* Regina Elena National Cancer Institute, Rome, Italy.
2008-2011 *Director*, Dept. of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, (Rome, Italy).
2006-2013 Affiliate Full Professor, Molecular and Microbiology Departmen and Life Sciences Department, College of Science, George Mason University, Fairfax, Virginia, USA.
2005-2011 *Scientific Director*, Mediterranean Institute of Oncology Foundation (IOM), (Catania, Italy).
2004-2008 *Director*, Division of Oncological and Hematological Biotechnologies, Dept. of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
2000-2003 *Research Director,* Hematology and Oncology laboratory, IstitutoSuperiore di Sanità, (Rome, Italy).
1998-1999 *Group leader,* Laboratory of Experimental Oncology, financed by AIRC, Pathology Institute, University of Catania, (Catania, Italy).
1998-2000 *Visiting Scientist*, Kimmel Cancer Institute, Thomas Jefferson University, (Philadelphia, USA).
1997-1999 *Research Instructor,* Laboratory *o*f Haematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, (Rome, Italy).
1996-1997 *Research Associate*, Signal Transduction, Dept. of Experimental Medicine and Biochemical Sciences, University "Tor Vergata", (Rome, Italy).
1993-1996 *Postdoctoral Fellow*, AIRC granted, Laboratory of Immunology, Dept. of Experimental Medicine, University "La Sapienza", (Rome, Italy).
1989-1994 *Postdoctoral Fellow,* Internal Medicine, University of Palermo, (Palermo, Italy).

OTHER SCIENTIFIC ACTIVITIES

2016-present *Visiting Professor West China Hospital, Sichuan University, Chengdu, China*
2016-present *Scientific Advisory Board,* Exiris, Rome, Italy

2015-present *Scientific Advisory Board,* National Foundation of Cancer Research, Bethesda, USA
2015-present *Member of the Scientific Advisory Board*f or the Cordeliers Research Centre (CRC-ISAB), Paris, France.
2015-present *Member* of the Scientific Committee for the Chiara D'Onofrio Foundation, Torino, Italy.
2014-present *Member of Steering Committee and Scientific Evaluation Committee;* ERA-NET Traslational Cancer Research, TRANSCAN.
2014-present *Member of the Scientific Advisory Board* for the Helmholtz Initiative on Personalised Medicine (iMED), Heidleberg, Germany.
2014-present *Member of the Scientific Committee* for Atena Onlus Foundation, Rome, Italy.
2014-present *Honorary Member* of the Academia Gioenia, University of Catania, Italy.
2013-present *Member of the Advisory Board of AIRC (Italian Association for Cancer Research).*
2013-present *Member of the Scientific Committee,* Umberto Veronesi Foundation, Italy.
2011-present *Coordinator* of research activities related to the AIRC (Italian Association for Cancer Research) Project under the "Special Program Molecular Clinical Oncology 5 per mille": 125 units of research staff.
2018 AACR Lung Cancer Research Grants Scientific Review Committee, Philadelphia, PA, USA
2016 *Panel member* for the Pezcoller Foundation EACR Cancer Researcher Award.
2015 Member State Funder's Representative, Personalised Medicine, Brussels, Belgium.
2014-2015 *Member of the Scientific Advisory Board* for the "Marie Skłodowska-Curie Innovative Training Network, Paris France.
2014-2015 *Member* of the Scientific Advisory Board for the Parisian Alliance of Cancer Research Institutes (PACRI), Paris France.
2013-2014 *Member* of the American Association for Cancer Research Committee for "Pezcoller Foundation AACR International Award".
2013-2014 *Member of the Scientific Committee* for "Stamina", Ministry of Health", Italy.
2012-2013 *Member* of the American Association for Cancer Research Committee for "2012 Landon Foundation - AACR INNOVATOR Award".
2013 *Member of the Scientific Committee* for "InBev-BAILLET LATOUR Health Prize", Bruxelles
2012 *Panel Board Member,* Cancer Research UK Program, London.
2011 *Member of the Technical Committee* for Environmental Authorization, Ministry of Evironment.
2009-2011 *Member of the Scientific Committee,* Center for Advanced Biotechnologies, Genoa, Italy.
2010-2011 *Member of the Scientific Advisory Board for cancer pipeline, Dompe Pharmaceuticals, Italy*.
2008-2010 *Member of the Scientific Advisory Board for lung cancer pipeline, Pfizer, USA*.
2008-2009 *Member of the Scientific Committeee,* IRCSS Neurological Institute Foundation "Carlo Besta", Milano, Italy.
2007-2009 *Scientific Consultant for translational Oncology,* Wyeth Pharmaceuticals, USA.
2007-2009 *Member of the Board Director* of the Centre of Advanced Biotechnologies, Genoa, Italy.
2005-2014 *Coordinator* of the Italy-US Programme "Oncoproteomics" & *Education, Coordinator* of the Research Scholarship Programme (42 Research Fellows).
2003-2011 *Member of the Scientific Committee* of the Italian Association for Cancer Research (AIRC).

EDITORIAL ACTIVITIES

- *Editor* of the Scientific Journal "Oncogene".
- *Editor* of the Scientific Journal "Cell Death and Differentiation".
- *Editor* of the Scientific Journal "Frontiers in Cancer Molecular Targets and Therapeutics".
- *Editor* of the Scientific Journal "Cell Death and Disease".
- *Editor* of the Scientific Journal "Human Genomics and Proteomics" (2009-2011).
- *Editor* of the Scientific Journal "Molecular & Cellular Oncology".
- *Editorial Advisory Board* of "Oncology in Clinical Practice" Journal.
- *Editor* of the Scientific Journal "Oncogenesis" Journal.
- *Editor* of the Scientific Journal "Signal Transduction and targeted therapy"
- *Member of Editorial Advisory* Board "Oncotarget" for the section: "Autophagy and Cell Death".

AWARDS, HONOUR AND PUBLIC COMPETITIONS

- International Award “Salerno School of Medicine”for Scientific Research, Salerno, Italy (2014);
- National Award “Timone d’argento 2014”, Italy (2014);
- "International Sebetia-TerAward", awarded by the President of the Italian Republic for Biomedical Science, University of Naples “Federico II”, Naples, Italy (2014);
- “Golden Medal of Honour for Public Health” – by the President of the Italian Republic – Rome, Italy (2013);
- Iternational Bioeconomy Prize in Molecular Biology, IRBM & Pfizer (2011);
- “Atena” Award, Advanced Neurosurgical Therapies Association, Rome, Italy (2010);
- “Grappolo d’oro” Award, Catania, Italy (2009);
- “Guido Venosta” Award, Italian Foundation for Cancer Research, by the President of the Italian Republic, Italy (2008);
- “Taormina per le Arti e le Scienze” Award, Taormina, Italy (2007);
- “Golden Tower” Award, Italy (2005);
- “Catania Talenti & Dintorni” Award, Catania, Italy (2005);
- “Adriano Buzzati-Traverso” Award, Rome, Italy (1998);
- "New Unit Start UP Grant" from the AIRC, Italian Association for Cancer Research (1998).
- “Servier Award”, Catholic University of Sacred Heart, Rome, Italy (1990).

MAJOR INSTITUTIONAL ACTIVITIES

2017-present	Italian coordinator of the Sino-Italian cooperation program on Oncology
2016-present	Italian coordinator of the MD Anderson Sister Institution Program
2016-present	Italian coordinator of the “Sino-Italian Laboratory on Genomics, Translational Medicine and Clinical Research on Lung Cancer"
2017-present	Responsible for the definition of the National Oncology Planning for 2018-2021
2014-present	Italian Delegate of the Ministry of Health for the International Cooperation in Oncology
2014-2015	President of the Selection Committee for the Italian FDA coordinators in Oncology and Pharmacoeconomics
2008-2011	Responsible for regulatory control of hemoderivative products for Italian Hospitals
2008-2011	Responsible for regulatory admission to phase I clinical trials of oncological therapeutics in Italy
2005-2011	Italian Coordinator of bilateral USA-Italy oncological research programs sponsored by NIH and Italian Ministry of Health

LIST OF SCIENTIFIC PUBLICATIONS

IF >8: n=80; total IF 1228,270; mean IF 15.353
IF>5: n=144; total IF 1618,224; mean IF f 11.238
H index 59; citations >17.354 on Scopus
H index 66; citations >24.029 on Scholar

LIST OF SCIENTIFIC PUBLICATIONS (1992-2018)

IMPACT FACTOR >20 (IF TOT 594.819 MEAN IF 33.046)

1. Marcucci F, Stassi G, De Maria R. Epithelial-mesenchymal transition: a new target in anticancerdrugdiscovery. **Nat Rev Drug Discov**. 2016 Jan 29. doi: 10.1038/nrd.2015.13. **IF 50.167**
2. Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, Chomienne C, Ishikawa F, Schuringa JJ, Stassi G, Huntly B, Herrmann H, Soulier J, Roesch A, Schuurhuis GJ, Wöhrer S, Arock M, Zuber J, Cerny-

Reiterer S, Johnsen HE, Andreeff M, Eaves C. Cancer stem cell definitions and terminology: the devil is in the details. **Nat Rev Cancer**. 2012 Nov;12(11):767-75. **IF 42.784**

3. Stassi G, De Maria R. Autoimmune thyroid disease: new models of cell death in autoimmunity. **Nat Rev Immunol**. 2002 Mar; 2(3):195-204. **IF 41.982**
4. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, Maira G, Parati EA, Stassi G, Larocca LM, De Maria R. Tumor vascularization via endothelial differentiation of glioblastoma stem-like cells. **Nature**. 2010 Dec 9; 468(7325):824-828. **IF 41.577**
5. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. Identification and expansion of human colon-cancer initiating cells. **Nature**. 2007 Jan4; 445(7123):111-115. **IF 41.577**
6. De Maria R, Zeuner A, Eramo A, Domenichelli C, Bonci D, Grignani F, Srinivasula SM, Almemri ES, Testa U, Peschle C. Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1. **Nature**. 1999 Sep 30; 401(6752):489-493. **IF 41.577**
7. Ziegler BL, Valtieri M, AlmeidaPorada G, De Maria R, Müller R, Masella B, Gabbianelli M, Casella I, Pelosi E, Bock T, ZanGeni ED, Peschle C. KDR receptor: a key marker defining hematopoietic stem cells. **Science**. 1999 Sep 3; 285(5433):1553-1558. **IF 41.058**
8. De Maria R, Lenti L, D'Agostino F, Zeuner A, Rippo MR, Malisan F, Tomassini B, Testi R. Requirement for GD3 ganglioside in CD95- and ceramide-induced apoptosis. **Science**. 1997 Sep 12; 277(5332):1652-1655. **IF 41.058**
9. Giordano C*, Stassi G*, De Maria R*, Todaro M, Richiusa P, Papoff G, Ruberti G, Bagnasco M, Testi R, Galluzzo A. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. **Science**. 1997 Feb 14; 275(5302):960-963. *Equalcontribution. **IF 41.058**
10. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, D'Urso L, Pagliuca A, Bartucci M, Muto G, Peschle C, De Maria R. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. **Nat Med**. Nov 2008; 14(11):1271-1277. **IF 32.621**
11. Haas TL, Sciuto MR, Brunetto L, Valvo C, Signore M, Fiori ME, di Martino S, Giannetti S, Morgante L, Boe A, Patrizii M, Warnken U, Schnölzer M, Ciolfi A, Di Stefano C, Biffoni M, Ricci-Vitiani L, Pallini R, De Maria R Integrin α7 Is a Functional Marker and Potential Therapeutic Target in Glioblastoma. **Cell Stem Cell.** 2017 6;21(1):35-50.e9. doi: 10.1016/j.stem.2017.04.009. **IF 23.290**
12. Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, Apuzzo T, Sperduti I, Volpe S, Cocorullo G, Gulotta G, Dieli F, De Maria R, Stassi G. CD44v6 Is a Marker of Constitutive and Reprogrammed Cancer Stem Cells Driving Colon CancerMetastasis. **Cell Stem Cell**. 2014 Mar 6;14(3):342-56. **IF 23.290**
13. Zeuner A, Todaro M, Stassi G, De Maria R. Colorectal cancer stem cells: from the crypt to the clinic.**Cell Stem Cell.** 2014 Dec 4;15(6):692-705. doi: 10.1016/j.stem.2014.11.01. **IF 23.290**
14. Zeuner A, De Maria R. Not so lonely at the top for Cancers Stem Cells. **Cell Stem Cell.** 2011 Oct 4;9(4):289-90. **IF 23.290**
15. F Stassi G, De Maria R. Response to 'Thyrocytes - not innocent bystanders in autoimmune disease'. **Nat Immunol**. 2001 Mar;2(3):183. **IF 21.809**
16. Stassi G, Di Liberto D, Todaro M, Zeuner A, Ricci-Vitiani L, Stoppacciaro A, Ruco L, Farina F, Zummo G, De Maria R. Control of target cell survival in thyroid autoimmunity by T helper cytokines via regulation of apoptotic proteins. **Nat Immunol**. 2000 Dec; 1(6):483-488. **IF 21.809**
17. Palmieri G, Gismondi A, Galandrini R, Milella M, Serra A, De Maria R, Santoni A. Interaction of natural killer cells with extracellular matrix induces early intracellular signalling events and enhances cytotoxic functions. **Nat Immun**. 1996-1997;15(2-3):147-53. **IF 21.809**
18. Lombardo Y, Scopelliti A, Cammareri P, Todaro M, Iovino F, Ricci-Vitiani L, Gulotta G, Dieli F, De Maria R, Stassi G. Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. **Gastroenterology**. 2011 Jan; 140(1):297-309. **IF 20.773**

IMPACT FACTOR >10 AND <20 (IF TOT 340.725 MEAN 12.619)

1. Manic G, Signore M, Sistigu A, Russo G, Corradi F, Siteni S, Musella M, Vitale S, De Angelis ML, Pallocca M, Amoreo CA, Sperati F, Di Franco S, Barresi S, Policicchio E, De Luca G, De Nicola F, Mottolese M, Zeuner A, Fanciulli M, Stassi G, Maugeri-Saccà M, Baiocchi M, Tartaglia M, Vitale I, De Maria R. CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells. **Gut**. 2018 May;67(5):903-917. doi: 10.1136/gutjnl-2016-312623 **IF 17.016**
2. Ricci-Vitiani L, Pagliuca A, Palio E, PegnaZeuner A, De Maria R. Colon cancer stem cells. **GUT**. 2008

Apr; 57(4):538-548. **IF 17.016**

3. Ortiz-Ferron, Yebes R, Eramo A, Palio E, Zeuner A, De Maria R, Lopez-Rivas A. Roscovitine sensitizes breast tumor cells to TRAIL-induced apoptosis through a pleiotropic mechanism. **Cell Res.** 2008 Jun;18(6):664-676. **IF 15.393**
4. Zeuner A, Pedini F, Francescangeli F, Signore M, Girelli G, Tafuri A, De Maria R. Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells. **BLOOD**. 2009 Feb; 113(7):1522-1525. **IF 15.132**
5. Zeuner A, Pedini F, Signore M, Ruscio G, Messina C, Tafuri A, Girelli G, Peschle C, De Maria R. Increased death receptor resistance and FLIP short expression in polycythemia vera erythroid precursor cells. **BLOOD**. 2006 May 1; 107(9):3495-3502. **IF 15.132**
6. Bonci D, Hahne M, Felli N, Peschle C, De Maria R. Potential role of APRIL as autocrine growth factor for megakaryocytopoiesis. **BLOOD**. 2004 Nov 15**;** 104(10):3169-3172. **IF 15.132**
7. Zeuner A, Pedini F, Signore M, Testa U, Pelosi E, Peschle C, De Maria R. Stem cell factor protects erythroid precursor cells from chemotherapeutic agents via up-regulation of BCL-2 family proteins. **BLOOD**. 2003 July 1; 102(1):87-93. **IF 15.132**
8. De Maria R, Testa U, Luchetti L, Zeuner A, Stassi G, Pelosi E, Riccioni R, Felli N, Samoggia P, Peschle C. Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis. **BLOOD**. 1999 Feb 1; 93(3):796-803. **IF 15.132**
9. Vitale I, Manic G, De Maria R, Kroemer G, Galluzzi L.DNA Damage in Stem Cells. **Mol Cell**. 2017 May 4;66(3):306-319. doi: 10.1016/j.molcel.2017.04.006 **IF 14.248**
10. De Maria R, Testi R. Fas/FasL interactions: a common pathogenetic mechanism in organ-specific autoimmunity. **Immunology Today**. 1998 Mar; 19(3):121-125. **IF 14.188**
11. Testi R, D'Ambrosio D, De Maria R, Santoni A. The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells. **Immunol Today**. 1994 Oct;15(10):479-83. **IF 14.188**
12. Boirivant M, Pica R, De Maria R, Testi R, Pallone F, Strober W. Stimulated human lamina propria T cells manifest enhanced Fas-mediated apoptosis. **J Clin Invest**. 1996 Jan;15; 98:2616-2622. **IF 13.251**
13. De Maria R, Boirivant M, Cifone MG, Roncaioli P, Hahne M, Tschopp J, Pallone F, Santoni A, Testi R. Functional expression of Fas and Fas ligand on human gut lamina propria T lymphocytes: A potential role for acidic shpingomyelinase pathway in normal immunoregulation. **J Clin Invest**. 1996; 97(2):316-322. **IF 13.251**
14. Ricci-Vitiani L, Pedini F, Mollinari C, Condorelli G, Bonci D, Bez A, Colombo A, Parati E, Peschle C, De Maria R. Absence of caspase 8 and high expression of PED protect primitive neuralcells from celldeath. **J Exp Med**. 2004 Nov 15**;** 200(10):1257-1266. **IF 10.790**
15. De Maria R, Rippo MR, Schuchman ES, Testi R. Acidic sphingomyelinase (ASM) is necessary for Fas-induced GD3 ganglioside accumulation and efficient apoptosis of lymphoid cells. **J Exp Med**. 1998 Mar 16; 187(6):897-902. **IF 10.790**
16. Stassi G, De Maria R, Trucco G, Rudert W, Testi R.A, Giordano C, Trucco M. Nitric oxide primes pancreatic beta cells for Fas-mediated destruction in insulin-dependent diabetes mellitus. **J Exp Med**. 1997 Oct 20; 186(8):1193-1200. **IF 10.790**
17. Sallusto F, Nicolò C, De Maria R, Corinti S, Testi R. Ceramide inhibits antigen uptake and presentation by dendritic cells. **J Exp Med**. 1996 Dec 1; 184(6):2411-2416. **IF 10.790**
18. De Maria R, Cifone MG, Trotta R, Rippo MR, Festuccia C, Santoni A, Testi R. Triggering of human monocyte activation through CD69, a member of the natural killer cell gene complex family of signal transducing receptors. **J Exp Med**. 1994 Nov 1;180(5):1999-2004. **IF 10.790**
19. Cifone MG, De Maria R, Roncaioli P, Rippo MR, Azuma M, Lanier LL, Santoni A, Testi R. Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase. **J Exp Med**. 1994 Oct 1;180(4):1547-52. **IF 10.790**
20. Cifone MG, Roncaioli P, De Maria R, Camarda G, Santoni A, Ruberti G, Testi R Multiple pathways originate at the Fas/APO-1 (CD95) receptor: sequential involvement of phosphatidylcholine-specific phospholipase C and acidic sphingomyelinase in the propagation of the apoptotic signal. **EMBO J**. 1995 Dec 1;14(23):5859-68. **IF 10,557**
21. Maugeri-Saccà M, De Maria R The Hippo pathway in normal development and cancer. **Pharmacol Ther.** 2018 Jun;186:60-72. doi: 10.1016/j.pharmthera.2017.12.011. **IF 10.376**
22. Bartucci M, Dattilo R, Martinetti D, Todaro M, Zapparelli G, Di Virgilio A, Biffoni M, De Maria R, Zeuner A. Prevention of chemotherapy-induced anemia and thrombocytopenia by constant administration of Stem Cell Factor. **Clin Cancer Res**. 2011 Oct 1;17(19):6185-91. **IF 10.199**
23. Maugeri M, Vigneri P, De Maria R. Molecular Pathways: Cancer Stem Cells and Chemosensitivity. **Clin. Cancer Res**. 2011 Aug 1;17(15):4942-7. **IF 10.199**

24. Pallini R, Ricci-Vitiani L, Banana GL, Signore M, Lombardi D, Todaro M, Stassi G, Martini M, Maira G, Larocca LM, De Maria R. Cancer stem cell analysis and clinical out come in patients with glioblastoma multiforme. **Clin Cancer Res**. 2008 Dec 15; 14(24):8205-8212**. IF 10.199**
25. Manic G, Sistigu A, Corradi F, Musella M, De Maria R, Vitale I Replication stress response in cancer stem cells as a target for chemotherapy. **Semin Cancer Biol** 2018 Aug; **IF 10.198**
26. Accordi B, Galla L, Milani G, Curtarello M, Serafin V, Lissandron V, Viola G, TeKronnie G, De Maria R, Petricoin EF 3rd, Liotta LA, Indraccolo S, Basso G. AMPK inhibition enhances apoptosis in MLL-rearranged pediatric B-acute lymphoblastic leukemia cells. **Leukemia**. 2013 Apr;27(5):1019-27. **IF 10.023**
27. Vicari L, Eramo A, Manzella L, Malaguarnera L, G Cannolo, Gulisano M, De Maria R, Messina A, Vigneri P. The PU.1 transcription factor induces cyclin D2 expression in U937 cells. **Leukemia**. 2006 Dec; 20(12):2208-2210. **IF 10.023**

IMPACT FACTOR > 8 AND <10 (IF TOT 292.726 MEAN 8.364)

1. D'Alessandris QG, Biffoni M, Martini M, Runci D, Buccarelli M, Cenci T, Signore M, Stancato L, Olivi A, De Maria R, Larocca LM, Ricci-Vitiani L, Pallini R The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response. **Neuro Oncol**. 2017 Aug 1;19(8):1097-1108. doi: 10.1093/neuonc/now304 **IF 9.384**
2. Todaro M, Turdo A, Bartucci M, Iovino F, Dattilo R, Biffoni M, Stassi G, Federici G, De Maria R, Zeuner A. Erythropoietin Activates Cell Survival Pathways in Breast Cancer Stem-like Cells to Protect Them from Chemotherapy. **Cancer Res.** 2013 Nov 1;73(21):6393-400. **IF 9.130**
3. Todaro M, Iovino F, Eterno V, Cammareri P, Gambara G, Espina V, Gullotta G, Dieli F, Giordano S, De Maria R, Stassi G. Tumorogenic and metastatic activity of human thyroid cancer stem cells. **Cancer Res**. 2010 Nov 1; 70(21):8874-8885. **IF 9.130**
4. Francipane MG, Etenro V, Spina V, Bini M, Scerrino G, Buscemi G, Gulotta G, Todaro M, Dieli F, De Maria R, Stassi G. Suppressor of cytokine signaling 3 sensitizes anaplastic thyroid cancer to standard chemotherapy. **Cancer Res**. 2009 Aug 1; 69(15):6141-6148. **IF 9.130**
5. Siragusa M, Zerilli M, Iovino F, Francipane MG, Lombardo Y, Ricci-Vitiani L, Di Gesù G, Todaro M, De Maria R, Stassi G. MUC1 oncoprotein promotes refractoriness to chemotherapy in thyroid cancer cells. **Cancer Res.** 2007 Jun 1; 67: 5522-5530. **IF 9.130**
6. Zeuner A, Signore M, Martinetti D, Bartucci M, Peschle C, De Maria R. Chemotherapy-induced thrombocytopenia derives from the selective death of megakaryocyte progenitors and can be rescued by stem cell factor. **Cancer Res.** 2007 May 15; 67(10):4767-4773. **IF 9.130**
7. Todaro M, Zerilli M, Ricci-Vitiani L, Bini M, Perez Alea M, Maria Florena A, Miceli L, Condorelli G, Bonventre S, Di Gesù G, De Maria R, Stassi G. Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells. **Cancer Res**. 2006 Feb 1**;** 66(3):1491-1499. **IF 9.130**
8. Eramo A, Pallini R, Lotti F, Sette G, Patti M, Bartucci M, Ricci-Vitiani L, Signore M, Stassi G, Larocca LM, Crino L, Peschle C, De Maria R. Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction. **Cancer Res**. 2005 Dec 15; 65(24):11469-11477. **IF 9.130**
9. Stassi G, Todaro M, Zerilli M, Ricci-Vitiani L, Di Liberto D, Patti M, A, Di Gaudio F, Di Gesù G, De Maria R.Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. **Cancer Res**. 2003 Oct 15; 63(20):6784-6790. **IF 9.130**
10. Bonci D, Musumeci M, Coppola V, Addario A, Conticello C, Hahne M, Gulisano M, Grignani F, De Maria R. Blocking the APRIL circuit enhances acute myeloid leukemia cell chemosensitivity. **Haematologica**. 2008 Dec; 93(12):1899-1902. **IF 9,090**
11. De Maria R, Grignani F, Testa U, Valtieri M, Ziegler BL, Peschle C. Gene regulation in normal and leukemic progenitor/stem cels. Haematologica. 1999 Jun; 84(Suppl. EHA-4):8-10. IF 9.090
12. Maugeri-Sacca M, Bartucci M, De Maria R. Checkpoint kinase 1 inhibitors for potentiating systemic anticancer therapy. **Cancer Treatment Reviews.**2013 Aug 39(5):525-33. **IF 8.122**
13. Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D'Angiolella V,

Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, DeBerardinis RJ, Deshmukh M, Di Daniele N, Di Virgilio F, Dixit VM, Dixon SJ, Duckett CS, Dynlacht BD, El-Deiry WS, Elrod JW, Fimia GM, Fulda S, García-Sáez AJ, Garg AD, Garrido C, Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA, Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS, Hengartner MO, Hetz C, Ichijo H, Jäättelä M, Joseph B, Jost PJ, Juin PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lowe SW, Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni W, Manic G, Marine JC, Martin SJ, Martinou JC, Medema JP, Mehlen P, Meier P, Melino S, Miao EA, Molkentin JD, Moll UM, Muñoz-Pinedo C, Nagata S, Nuñez G, Oberst A, Oren M, Overholtzer M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM, Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L, Shao F, Shi Y, Silke J, Simon HU, Sistigu A, Stockwell BR, Strasser A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A, Tsujimoto Y, Turk B, Vanden Berghe T, Vandenabeele P, Vander Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D, Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W, Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G, Kroemer G. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. **Cell Death Differ.** 2018 Mar;25(3):486-541. doi: 10.1038/s41418-017-0012-4. **IF 8.000**

14. Cianfrocca R, Rosanò L, Tocci P, Sestito R, Caprara V, Di Castro V, De Maria R, Bagnato A.Blocking endothelin-1-receptor/β-catenin circuit sensitizes to chemotherapy in colorectal cancer. **Cell Death Differ**. 2017 Oct;24(10):1811-1820. doi: 10.1038/cdd.2017.121 **IF 8.000**
15. Francescangeli F, Contavalli P, De Angelis ML, Baiocchi M, Gambara G, Pagliuca A, Fiorenzano A, Prezioso C, Boe A, Todaro M, Stassi G, Castro NP, Watanabe K, Salomon DS, De Maria R, Minchiotti G, Zeuner A. Dynamic regulation of the cancer stem cell compartment by Cripto-1 in colorectal cancer. **Cell Death Differ**. 2015 Oct;22(10):1700-13. doi: 10.1038/cdd.2015.19. Epub 2015 Mar 20**. IF 8.000**
16. Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, Alnemri ES, Altucci L, Andrews D, Annicchiarico-Petruzzelli M, Baehrecke EH, Bazan NG, Bertrand MJ, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C, Campanella M, Candi E, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, Di Daniele N, Dixit VM, Dynlacht BD, El-Deiry WS, Fimia GM, Flavell RA, Fulda S, Garrido C, Gougeon ML, Green DR, Gronemeyer H, Hajnoczky G, Hardwick JM, Hengartner MO, Ichijo H, Joseph B, Jost PJ, Kaufmann T, Kepp O, Klionsky DJ, Knight RA, Kumar S, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lugli E, Madeo F, Malorni W, Marine JC, Martin SJ, Martinou JC, Medema JP, Meier P, Melino S, Mizushima N, Moll U, Muñoz-Pinedo C, Nuñez G, Oberst A, Panaretakis T, Penninger JM, Peter ME, Piacentini M, Pinton P, Prehn JH, Puthalakath H, Rabinovich GA, Ravichandran KS, Rizzuto R, Rodrigues CM, Rubinsztein DC, Rudel T, Shi Y, Simon HU, Stockwell BR, Szabadkai G, Tait SW, Tang HL, Tavernarakis N, Tsujimoto Y, Vanden Berghe T, Vandenabeele P, Villunger A, Wagner EF, Walczak H, White E, Wood WG, Yuan J, Zakeri Z, Zhivotovsky B, Melino G, Kroemer G. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 **Cell Death Differ.** 2015 Jan;22(1):58-73. doi: 10.1038/cdd.2014.137 **IF 8.000**
17. Zeuner A, Francescangeli F, Contavalli P, Zapparelli G, Apuzzo T, Eramo A, Baiocchi M, De Angelis ML, Biffoni M, Sette G, Todaro M, Stassi G, De Maria R. Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer. **Cell Death Differ**. 2014 Dec;21(12):1877-88. doi: 10.1038/cdd.2014.105. **IF 8.000**.
18. Fiori ME, Barbini C, Haas TL, Marroncelli N, Patrizii M, Biffoni M, De Maria R. Antitumor effect of miR-197 targeting in p53 wild-type lung cancer. **Cell Death Differ.** 2014 May;21(5):774-82. **IF 8.000**
19. Ciceroni C, Bonelli M, Mastrantoni E, Niccolini C, Laurenza M, LaroccaLM, Pallini R, Traficante A, Spinsanti P, Ricci-Vitiani L, Arcella A, De Maria R, Nicoletti F, Battaglia G, Melchiorri D. Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas. **Cell Death Differ.** 2013 Mar;20(3)396-407. **IF 8.000**
20. Bartucci M, Svensson S, Romania P, Dattilo R, Patrizii M, Signore M, Navarra S, Lotti F, Biffoni M, Pilozzi E, Duranti E, Martinelli S, Rinaldo C, Zeuner A, Maugeri-Saccà M, Eramo A, De Maria R. Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. **Cell Death and Differ.** 2012 May 19(5):768-778. **IF 8.000**
21. Zeuner A, De Maria R. Reprogramming: So simple, so complex. **Cell Death Differ.** 2012 Aug;19(8):1253-4. **IF 8.000**
22. Tate CM, Pallini R, Ricci-Vitiani L, Dowless M, Shiyanova T, D'Alessandris GQ, Morgante L, Giannetti S, Larocca LM, di Martino S, RowlinsonSW, De Maria R, Stancato L. A BMP7 variant inhibits the tumorigenic potential of glioblastoma stem-like cells. **Cell Death Differ**. 2012 Oct;19(10):1644-54. **IF 8.000**

23. Zeuner A, Francescangeli F, Signore M, Venneri MA, Pedini F, Felli N, Pagliuca A, Conticello C, De Maria R. The Notch2-Jagged1 interaction mediates stem cell factor signaling in erythropoiesis. **Cell Death Differ**. 2011 Feb; 18(2):371-80. **IF 8.000**
24. Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Ashkenazi A, Baehrecke EH, Bazan NG, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C, Castedo M, Cidlowski JA, Ciechanover A, Cohen GM, De Laurenzi V, De Maria R, Deshmukh M, Dynlacht BD, El-Deiry WS, Flavell R A, Fulda S, Garrdio C, Golstein P, Gougeon ML, Green DR, Gronemeyer H, Hajnòczky G, Hardwick JM, Hengartner M, Ichijo H, Jaattela M, Kepp O, Kimchi A, Klinsky DJ, Knight RA, Kornbluth S, Kumar S, Levine B, Lipton SA, Lugli E, Madeo F, Malorni W, Marine J-C W, Martin SJ, Medema JP, Mehlen P, Melino G, Moll UM, Morselli E, Nagata S, Nicholson DW, Nicotera P, Nunez G, Oren M, Penninger J, Pervaiz S, Peter ME, Piacentini M, Prehn JHM, Puthalakath H, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Scorrano L, Simon H-U, Steller H, Tschopp J, Tsujimoto Y, Vandenabeele P, Vitale I, Vousden KH, Youle RJ, Yuan J, Zhivotovsky B and Kroemer G. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. **Cell Death Differ**. 2009 Aug; 16(8):1093-1107. **IF 8.000**
25. Ricci Vitiani L, Pallini R, Larocca LM, Lombardi DG, Signore M, Pierconti F, Petrucci G, Motano M, Maira G, De Maria R. Mesenchymal differentiation of glioblastoma stem cells. **Cell Death Differ**. 2008 Sep; 15(9):1491-1498. **IF 8.000**
26. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, De Maria R. Identification and expansion of the tumorigenic lung cancer stem cell population. **Cell Death Differ**. 2008 Mar; 15(3):504-514. **IF 8.000**
27. Ricci-Vitiani L, Lombardi DG, Signore M, Biffoni M, Pallini R, Parati E, Peschle C, De Maria R. Human neural progenitor cells display limited cytotoxicity and increased oligodendrogenesis during inflammation. **Cell Death Differ**. 2007 Apr;14(4):876-878. **IF 8.000**
28. Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G, Pilozzi E, Larocca LM, Peschle C, De Maria R. Chemotherapy resistance of glioblastoma stem cells. **Cell Death Differ**. 2006 Jul**;** 13(7):1238-1241. **IF 8.184**
29. Coppola S, Narciso L, Feccia T, Bonci D, Calabro L, Morsilli O, Gabbianelli M, De Maria R, Testa U, Peschle C. Enforced expression of KDR receptor promotes proliferation, survival and megakaryocytic differentiation of TF1 progenitor cell line. **Cell Death Differ**. 2006 Jan; 13(1):61-74. **IF 8.000**
30. Di Giorgi-Gerevini V, Melchiorri D, Battaglia G, Ricci-Vitiani L, Ciceroni C, Busceti CL, Biagioni F, Iacovelli L, Canudas AM, Parati E, De Maria R, Nicoletti F. Endogenous activation of metabotropic glutamate receptors supports the proliferation and survival of neural progenitor cells. **Cell Death Differ**. 2005 Aug; 12(8):1124-33. **IF 8.000**
31. Zeuner A, Eramo A, Testa U, Felli N, Pelosi E, Mariani G, Srinivasula SM, Alnemri ES, Condorelli G, Peschle C, De Maria R. Control of erythroidcell production via caspase-mediated cleavage of transcription factor SCL/Tal-1. **Cell Death Differ**. 2003 Aug**;** 10(8):905-913. **IF 8.000**
32. Conte E, Manzelli L, Zeuner A, Cocchiaro G, Conticello C, Zammataro L, Messina CG, De Maria R, Messina A. Involvement of interferon regulatory factor-1 in monocyte CD95 expression and CD95-mediated apoptosis. **Cell Death Differ**. 2003 May**;** 10(5):615-617. **IF 8.000**
33. Melchiorri D, Martini F, Lococo E, Gradini R, Barletta E, De Maria R, Caricasole A, Nicoletti F, Lenti L. An early increase in the disialoganglioside GD3 contributes to the development of neuronal apoptosis in culture. **Cell Death Differ**. 2002 June; 9(6):609-615. **IF 8.000**
34. Zeuner A, Ricci-Vitiani L, Conticello C, De Maria R. Death in 2000 ways. **Cell Death Differ**. 2000 Nov; 7(11):1140-1144. **IF 8.000**
35. Zeuner A, Eramo A, Peschle C, De Maria R. Caspase activation without death. **Cell Death Differ**. 1999 Nov; 6(11):1075-1080. **IF 8.000**

IMPACT FACTOR > 5 AND <8 (IF TOT 389.954 MEAN 6.093)

1. Todaro M, Zerilli M, Triolo G, Iovino F, Patti M, Accardo-Palumbo A, Di Gaudio F, Turco MC, Petrella A, De Maria R, Stassi G. NF-kappa B protects Behcet's disease T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins. **Arthritis Rheum**. 2005 Jul**;** 52(7):2179-2191. **IF 7.871**
2. Del Bufalo D, Desideri M, De Luca T, Di Martile M, Gabellini C, Monica V, Busso S, Eramo A, De Maria R, Milella M, Trisciuoglio D Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer. **Mol Cancer**. 2014 Oct 9;13:230. **IF 7.706**

3. Sette G, Salvati V, Giordani I, Pilozzi E, Quacquarini D, Duranti E, De Nicola F, Pallocca M, Fanciulli M, Falchi M, Pallini R, De Maria R, Eramo A. Conditionally reprogrammed cells (CRC) methodology does not allow the in vitro expansion of patient-derived primary and metastatic lung cancer cells. **Int J Cancer**. 2018 Jul 1;143(1):88-99. doi: 10.1002/ijc.31260 **IF 7.360**
4. Ronchetti L, Melucci E, De Nicola F, Goeman F, Casini B, Sperati F, Pallocca M, Terrenato I, Pizzuti L, Vici P, Sergi D, Di Lauro L, Amoreo CA, Gallo E, Diodoro MG, Pescarmona E, Vitale I, Barba M, Buglioni S, Mottolese M, Fanciulli M, De Maria R, Maugeri-Saccà M.DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. **Int J Cancer.** 2017 Jun 1;140(11):2587-2595. doi: 10.1002/ijc.30668. Epub 2017 Mar 11. **IF 7.360**
5. Morelli MB, Nabissi M, Amantini C, Farfariello V, Ricci-Vitiani L, di Martino S, Pallini R, Larocca LM, Caprodossi S, Santoni M, De Maria R, Santoni G. The transient receptor potential vanilloid-2 cation cannel impairs glioblastoma stem-like cell proliferation and promotes differentiation. **Int J Cancer**. 2012 Oct 1;131(7):E1067-77. **IF7.360**
6. Conticello C, Martinetti D, Adamo L, Buccheri S, Giuffrida R, Parrinello N, Lombardo L, Anastasi G, Amato G, Cavalli M, Chiarenza A, De Maria R, Giustolisi R, Gulisano M, Di Raimondo F. Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies. **Int J Cancer**. 2012 Nov 1;131(9):2197-203. **IF 7.360**
7. Di Lauro L, Pizzuti L, Barba M, Sergi D, Sperduti I, Mottolese M, Amoreo CA, Belli F, Vici P, Speirs V, Santini D, De Maria R, Maugeri-Saccà M Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis. **J Hematol Oncol**. 2015 May 17;8:53. doi: 10.1186/s13045-015-0147-z **IF 7.333**
8. Di Martino S, Amoreo CA, Nuvoli B, Galati R, Strano S, Facciolo F, Alessandrini G, Pass HI, Ciliberto G, Blandino G, De Maria R, Cioce M. HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome. **Oncogene**. 2018 Mar;37(10):1369-1385. doi: 10.1038/s41388-017-0044-8 **IF 6.854**
9. Po A, Silvano M, Miele E, Capalbo C, Eramo A, Salvati V, Todaro M, Besharat ZM, Catanzaro G, Cucchi D, Coni S, Di Marcotullio L, Canettieri G, Vacca A, Stassi G, De Smaele E, Tartaglia M, Screpanti I, De Maria R, Ferretti E. Noncanonical GLI1 signaling promotes stemness features and in vivo growth in lung adenocarcinoma **Oncogene**. 2017 Aug 10;36(32):4641-4652. doi: 10.1038/onc.2017 **IF 6.854**
10. Cannistraci A, Federici G, Addario A, Di Pace AL, Grassi L, Muto G, Collura D, Signore M, De Salvo L, Sentinelli S, Simone G, Costantini M, Nanni S, Farsetti A, Coppola V, De Maria R, Bonci D. C-Met/miR-130b axis as novel mechanism and biomarker for castration resistance state acquisition **Oncogene**. 2017 Jun 29;36(26):3718-3728. doi: 10.1038/onc.2016.505 **IF 6.854**
11. Bonci D, Coppola V, Patrizii M, Addario A, Cannistraci A, Francescangeli F, Pecci R, Muto G, Collura D, Bedini R, Zeuner A, Valtieri M, Sentinelli S, Benassi MS, Gallucci M, Carlini P, Piccolo S, De Maria R. A microRNA code for prostate cancer metastasis. **Oncogene.** 2015 Jun 15. doi: 10.1038/onc.2015.176. **IF 6.854**
12. Trono P, Di Modugno F, Circo R, Spada S, Di Benedetto A, Melchionna R, Palermo B, Matteoni S, Soddu S, Mottolese M, De Maria R, Nisticò P. hMENA11a contributes to HER3-mediated resistance to PI3K inhibitors in HER2 overexpressing breast cancer cells. **Oncogene**. 2015 May 11. doi: 10.1038/onc.2015.143. [Epub ahead of print] **IF 6.854**
13. Zane M, Scavo E, Catalano V, Bonanno M, Todaro M, De Maria R, Stassi. G Normal vs cancer thyroid stem cells: the road to transformation. **Oncogene**. 2015 May 11. doi: 10.1038/onc.2015.138. [Epub ahead of print]. **IF 6.854**
14. Bartucci M, Dattilo R, Moriconi C, Pagliuca A, Mottolese M, Federici G, Di Benedetto A, Todaro M, Stassi G, Sperati F, Amabile MI, Pilozzi E, Biffoni M, Patrizii M, Maugeri Saccà M, Piccolo S, De Maria R. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. **Oncogene**. 2014 Feb 17 [Epubahead of print]. **IF 6.854**
15. Coppola V, Musumeci M, Patrizii M, Cannistraci A, Addario A, Maugeri-Sacca M, Biffoni M, Francescangeli F, Cordenonsi M, Piccolo S, Memeo L, Pagliuca A, Muto G, Zeuner A,De Maria R, Bonci D. BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial-mesenchymal transition. **Oncogene**. 2013 Apr 4;32(14): 1843-53. **IF 6.854**
16. Pagliuca A, Valvo C, Fabrizi E, di Martino S, Biffoni M, Runci D, Forte S, De Maria R, Ricci-Vitiani L. Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. **Oncogene.** 2013 Oct;32(40):4806-13. **IF 6.854**
17. Musumeci M, Coppola V, Addario A, Patrizii M, Maugeri-Saccà M, Memeo L, Colarossi C, Francescangeli F, Biffoni M, Collura D, Giacobbe A, D'Urso L, Falchi M, Venneri MA, Muto G, De Maria R, Bonci D. Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. **Oncogene**. 2011 Oct 13;30(41):4231-42. **IF 6.854**

18. Eramo A, Haas TL, De Maria R. Lung cancer stem cells: tools and targets to fight lung cancer. **Oncogene**. 2010 Aug 19; 29(33):4625-4635. **IF 6.854**
19. Fanelli M, Capogrossi S, Ricci-Vitiani L, Porcellini A, Tomassoni-Ardori F, Amatori S, Andreoni F, Magnani M, De Maria R, Santoni A, Minucci S, Pelicci PG. Loss of pericentromeric DNA methylation pattern in human glioblastoma is associated with altered DNA methyltransferases espresion and involves the stem cell compartment. **Oncogene**. 2008 Jan 10; 27(3):358-365. **IF 6.854**
20. Martini M, Cenci T, D'Alessandris GQ, Cesarini V, Cocomazzi A, Ricci-Vitiani L, De Maria R, Pallini R, Larocca LM Epigenetic silencing of Id4 identifies a glioblastoma subgroup with a better prognosis as a consequence of an inhibition of angiogenesis. **Cancer.** 2013 Mar 1;119(5):1004-12. doi: 10.1002/cncr.27821 **IF 6.537**
21. Pallini R, Ricci-Vitiani L, Montano N, Mollinari C, Biffoni M, Cenci T, Pierconti F, Martini M, De Maria R, Larocca LM Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis. **Cancer** 2011 Jan 1;117(1):162-74. **IF 6,537**
22. Di Lauro L, Barba M, Pizzuti L, Vici P, Sergi D, Di Benedetto A, Mottolese M, Speirs V, Santini D, De Maria R, Maugeri-Saccà M. Androgen receptor and antiandrogen therapy in male breast cancer. **Cancer Lett**. 2015 Nov 1;368(1):20-5. doi: 10.1016/j.canlet.2015.07.040. Epub 2015 Aug 11. **IF 6.491**
23. Signore M, Ricci-Vitiani La, De Maria R. Targeting apoptosis pathways in cancer stem cells. **Cancer Letters.** 2013 May-28 332(2): 374-8. **IF 6.491**
24. Cirone M, De Maria R, D'Alessandro A, Frati L, Faggioni A, Ragona G. Epstein-Barr virus DNA is present both in CD10/CD77 positive and negative subsets of human tonsillar lymphocytes. **Cancer Letters** 1995 Feb 10;89(1):125-8. **IF 6.491**
25. Fiori ME, Villanova L, De Maria R. Cancer stem cells: at the forefront of personalized medicine and immunotherapy. **Curr Opin Pharmacol**. 2017 Aug;35:1-11. **IF 6.313**
26. Baiocchi M, Biffoni M, Ricci-Vitiani L, Pilozzi E, De Maria R. New models for cancer research: human cancer stem cell xenografts. **Curr Opin Pharmacol**. 2010 Aug;10(4):380-4. **IF 6.313**
27. Rotili D, Tarantino D, Nebbioso A, Paolini C, Huidobro C, Lara E, MelliniP,Lenoci A, Pezzi R, Botta G, Lahtela-Kakkonen M, Poso A, Steinkühler C, Gallinari P, De Maria R, Fraga M, Esteller M, Altucci L, Mai A. Discovery osalermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells. **J Med Chem**. 2012 Dec 27;55(24):10937-47. **IF 6.253**
28. Rotili D, Tarantino D, Carafa V, Paolini C, Schemies J, Jung M, Botta G, Di Maro S, Novellino E, Steinkühler C, De Maria R, Gallinari P, Altucci L, Mai A. Benzodeazaoxaflavins as sirtuin inhibitors with antiproliferative properties in cancer stem cells. **J MedChem.** 2012 Sep 27;55(18):8193-7. **IF 6.253**
29. Del Curatolo A, Conciatori F, Cesta Incani U, Bazzichetto C, Falcone I, Corbo V, D'Agosto S, Eramo A, Sette G, Sperduti I, De Luca T, Marabese M, Shirasawa S, De Maria R, Scarpa A, Broggini M, Del Bufalo D, Cognetti F, Milella M, Ciuffreda L. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. **J Exp Clin Cancer Res**. 2018 Jul 9;37(1):140. doi: 10.1186/s13046-018-0820-5. **IF 6.217**
30. Vici P, Ercolani C, Di Benedetto A, Pizzuti L, Di Lauro L, Sperati F, Terrenato I, Gamucci T, Natoli C, Di Filippo F6, Botti C, Barba M, Mottolese M, De Maria R, Maugeri-Saccà M Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy. **J Exp Clin Cancer Res.** 2016 Apr 2;35:62. doi: 10.1186/s13046-016-0338-7. **IF 6.217**
31. Di Lauro L, Pizzuti L, Barba M, Sergi D, Sperduti I, Mottolese M, Del Medico P, Belli F, Vici P, De Maria R, Maugeri-Saccà M. Efficacy of chemotherapy in metastatic male breast cancer patients: a retrospective study. **J Exp Clin Cancer Res**. 2015 Mar 21;34:26. **IF 6.217**
32. Sette G, Fecchi K, Salvati V, Lotti F, Pilozzi E, Duranti E, Biffoni M, Pagliuca A, Martinetti D, Memeo L, Milella M, De Maria R, Eramo A Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts **J Exp Clin Cancer Res.** 2013 Nov 16;32:91. doi: 10.1186/1756-9966-32-91. **IF 6.217**
33. Giordano C, De Maria R, Stassi G, Todaro M, Richiusa P, Giordano M, Testi R, Galluzzo A.Defective expression of the apoptosis-inducing CD95 (Fas/APO-1) molecule on T and B cells in IDDM. **Diabetologia**. 1995 Dec;38(12):1449-54. **IF 6.023**
34. Giordano C, Stassi G, Todaro M, De Maria R, Richiusa P, Scorsone A, Giordano M, Galluzzo A. Low bcl-2 expression and increased spontaneous apoptosis in T-lymphocytes from newly-diagnosed IDDM patients. **Diabetologia**. 1995 Aug;38(8):953-8 **IF 6.023**
35. Copani A, Melchiorri D, Caricasole A, Martini F, Sale P, Carnevale R, Gradini R, Sortino MA, Lenti L, De Maria R, F Nicoletti. Beta-amyloid-induced synthesis of the ganglioside GD3 is a requisite for cell cycle reactivation and apoptosis in neurons. **J Neurosci**. 2002 May 15; 22(10):3963-3968. **IF 5.970**

36. Conticello E, Adamo L, Giuffrida R, Vicari L, Zeuner A, Eramo A, Anastasi G, Memeo L, Giuffrida D, Iannolo G, Gulisano M, De Maria R. Proteasome inhibitors synergize with TRAIL to induce anaplastic thyroid carcinoma cell death. **J Clin Endocr Metab**. 2007 May; 92: 1938-1942. **IF 5.789**
37. Fiori ME, Villanova L, Barbini C, De Angelis ML, De Maria R miR-663 sustains NSCLC by inhibiting mitochondrial outer membrane ermeabilization (MOMP) through PUMA/BBC3 and BTG2. **Cell Death Dis**. 2018 Jan 19;9(2):49. doi: 10.1038/s41419-017-0080-x. **IF 5.638**
38. Sette G, Salvati V, Mottolese M, Visca P, Gallo E, Fecchi K, Pilozzi E, Duranti E, Policicchio E, Tartaglia M, Milella M, De Maria R, Eramo A. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer. **Cell Death Dis.** 2015 Aug 6;6:e1850. doi: 10.1038/cddis.2015.217**. IF 5.638**
39. Signore M, Pelacchi F, di Martino S, Runci D, Biffoni M, Giannetti S, Morgante L, De Majo M, Petricoin EF, Stancato L, Larocca LM, De Maria R, Pallini R, Ricci-Vitiani L. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo. **Cell Death Dis.** 2014 May 8;5:e1223. **IF 5.638**
40. Ricci-Vitiani L, Mollinari C, Di Martino S, Biffoni M, Pilozzi E, Pagliuca A, Chiara de Stefano M, Circo R, Merlo D, De Maria R, Garaci E. Thymosin {beta}4 targeting impairs tumorigenic activity of colon cancer stem cells. **Faseb J**. 2010 Nov; 24(11):4291-301. **IF 5.595**
41. Francescangeli F, Patrizii M, Signore M, Federici G, Di Franco S, Pagliuca A, Baiocchi M, Biffoni M, Ricci Vitiani L, Todaro M, De Maria R, Zeuner A. Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells. **Stem Cells.** 2012 Sep;30(9):1819-30. **IF 5.587**
42. Buglioni S, Vici P, Sergi D, Pizzuti L, Di Lauro L, Antoniani B, Sperati F, Terrenato I, Carosi M, Gamucci T, Vincenzoni C, Mariani L, Vizza E, Venuti A, Sanguineti G, Gadducci A, Barba M, Natoli C, Vitale I, Mottolese M, De Maria R, Maugeri-Saccà M Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment. **Oncoimmunology.** 2016 Mar 28;5(6):e1160187. doi: 10.1080/2162402X.2016.1160187 **IF 5.503**
43. Musella M, Manic G, De Maria R, Vitale I, Sistigu A Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications. **Oncoimmunology**. 2017 Apr 5;6(5):e1314424. doi: 10.1080/2162402X.2017.1314424 **IF 5.503**
44. Conticello C, Adamo L, Giuffrida R, Vicari L, Zeuner A, Eramo A, Anastasi G, Memeo L, Giuffrida D, Iannolo G, Gulisano M, **De Maria R.** Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis induced ligand to induce anaplastic thyroid carcinoma cell death. **J Clin Endocrinol Metab**. 200 May;92(5):1938-42. **IF 5.455**
45. Minasi MG, Riminucci M, De Angelis L, Borello U, Berarducci B, Innocenzi A, Caprioli A, Sirabella D, Baiocchi M, De Maria R, Bratto R, Jaffredo T, Broccoli V, Bianco P, Cossu G. The meso-angioblast: a multipotent, self-renewing cell that originates from the dorsal aorta and differentiates into most mesodermal tissues. **Development**. 2002 June; 129(11):2773-2784. **IF 5.414**
46. Maugeri-Saccà M, Bartucci M, De Maria R. DNA damage repair pathways in cancer stem cells. **Mol Cancer Ther.** 2012 Aug;11(8):1627-36. **IF 5.365**
47. Fiori ME, Villanova L, De Maria R Cancer stem cells: at the forefront of personalized medicine and immunotherapy **Curr Opin Pharmacol**. 2017 Aug;35:1-11. doi: 10.1016/j.coph.2017.04.006 **IF 5.363**
48. Baiocchi M, Biffoni M, Ricci-Vitiani L, Pilozzi E, De Maria R. New models for cancer research: human cancer stem cell xenografts. **Curr Opin Pharmacol**. 2010 Aug;10(4):380-4. doi: 10.1016/j.coph.2010.05.002 **IF 5.363**
49. Bartucci M, Svensson S, Ricci-Vitiani L, Dattilo R, Biffoni M, Signore M, Ferla R, De Maria R, Surmacz E. Obesity hormone leptin induces growth and interferes with the cytotoxic effects of 5-fluorouracil in colorectal tumor stem cells. **Endocr Relat Cancer**. 2010 Aug 16;17(3):823-33. **IF 5.331**
50. Coppola V, De Maria R, Bonci D. MicroRNAs and prostate cancer. **Endocr Relat Cancer**. 2010 Jan 29;17(1):F1-17 **IF 5.331**
51. Sciuto MR, Warnken U, Schnölzer M, Valvo C, Brunetto L, Boe A, Biffoni M, Krammer PH, De Maria R, Haas TL Two-Step Coimmunoprecipitation (TIP) Enables Efficient and Highly Selective Isolation of Native Protein Complexes. **Mol Cell Proteomics**. 2018 May;17(5):993-1009. doi: 10.1074/mcp.O116.065920 **IF 5.232**
52. Manic G, De Maria R, Vitale I. Replication stress in colorectal cancer stem cells. **Oncotarget**. 2017 May 20;8(53):90606-90607. doi: 10.18632/oncotarget.18045 **IF 5.168**
53. Vici P, Pizzuti L, Michelotti A, Sperduti I, Natoli C, Mentuccia L, Di Lauro L, Sergi D, Marchetti P, Santini D, Magnolfi E, Iezzi L, Moscetti L, Fabbri A, Cassano A, Grassadonia A, Omarini C, Piacentini F, Botticelli A, Bertolini I, Scinto AF, Zampa G, Mauri M, D'Onofrio L, Sini V, Barba M, Maugeri-Saccà M, Rossi E,

Landucci E, Tomao S, Alberti AM, Giotta F, Ficorella C, Adamo V, Russo A, Lorusso V, Cannita K, Barni S, Laudadio L, Greco F, Garrone O, Della Giulia M, Marolla P, Sanguineti G, Di Cocco B, Ciliberto G, De Maria R, Gamucci T. A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. **Oncotarget**. 2017 May 25;8(34):56921-56931. doi: 10.18632/oncotarget.18176 **IF 5.168**

54. Parasido EM, Silvestri A, Canzonieri V, Belluco C, Diodoro MG, Milione M, Melotti F, De Maria R, Liotta L, Petricoin EF, Pierobon M. Protein drug target activation homogeneity in the face of intra-tumor heterogeneity: implications for precision medicine. **Oncotarget**. 2017 Jul 25;8(30):48534-48544. doi: 10.18632/oncotarget **IF 5.168**
55. Bon G, Loria R, Amoreo CA, Verdina A, Sperduti I, Mastrofrancesco A, Soddu S, Diodoro MG, Mottolese M, Todaro M, Stassi G, Milella M, De Maria R, Falcioni R Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers. **Oncotarget**. 2016 Aug 19;8(65):108463-108479. doi: 10.18632/oncotarget **IF 5.168**
56. Di Benedetto A, Mottolese M, Sperati F, Ercolani C, Di Lauro L, Pizzuti L, Vici P, Terrenato I, Sperduti I, Shaaban AM, Sundara-Rajan S, Barba M, Speirs V, De Maria R, Maugeri-Saccà M.The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer. **Oncotarget**. 2016 Jul 12;7(28):43188-43198. doi: 10.18632/oncotarget.9668. **IF 5.168**
57. Vici P, Pizzuti L, Sperduti I, Frassoldati A, Natoli C, Gamucci T, Tomao S, Michelotti A, Moscetti L, Gori S, Baldini E, Giotta F, Cassano A, Santini D, Giannarelli D, Di Lauro L, Corsi DC, Marchetti P, Sini V, Sergi D, Barba M, Maugeri-Saccà M, Russillo M, Mentuccia L, D'Onofrio L, Iezzi L, Scinto AF, Da Ros L, Bertolini I, Basile ML, Rossi V, De Maria R, Montemurro F. "Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome. **Oncotarget**. 2016 Apr 5;7(14):17932-44. doi: 10.18632/oncotarget.7480. **IF 5.168**
58. Di Martile M, Desideri M, De Luca T, Gabellini C, Buglioni S, Eramo A, Sette G, Milella M, Rotili D, Mai A, Carradori S, Secci D, De Maria R, Del Bufalo D, Trisciuoglio D. Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells. **Oncotarget**. 2016 Mar 8;7(10):11332-48. doi: 10.18632/oncotarget.7238 **IF 5.168**
59. Vici P, Di Benedetto A, Ercolani C, Pizzuti L, Di Lauro L, Sergi D, Sperati F, Terrenato I, Dattilo R, Botti C, Fabi A, Ramieri MT, Mentuccia L, Marinelli C, Iezzi L, Gamucci T, Natoli C, Vitale I, Barba M, Mottolese M, De Maria R, Maugeri-Saccà M. Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis**. Oncotarget**. 2015 Oct 17. doi: 10.18632/oncotarget.6001. **IF 5.168**
60. Lulli V, Buccarelli M, Martini M, Signore M, Biffoni M, Giannetti S, Morgante L, Marziali G, Ilari R, Pagliuca A, Larocca LM, De Maria R, Pallini R, Ricci-Vitiani L. miR-135b suppresses tumorigenesis in glioblastoma stem-like cells impairing proliferation, migration and self-renewal. **Oncotarget.** 2015 Nov 10;6(35):37241-56. doi: 10.18632/oncotarget.5925. **IF 5.168**
61. Bongiorno-Borbone L, Giacobbe A, Compagnone M, Eramo A, De Maria R, Peschiaroli A, Melino G. Anti-tumoral effect of desmethylclomipramine in lung cancer stem cells. **Oncotarget**. 2015 Jul 10;6(19):16926-38**. IF 5.168**
62. Vici P, Mottolese M, Pizzuti L, Barba M, Sperati F, Terrenato I, Di Benedetto A, Natoli C, Gamucci T, Angelucci D, Ramieri MT, Di Lauro L, Sergi D, Bartucci M, Dattilo R, Pagliuca A, De Maria R, Maugeri-Saccà M. The Hippotransducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy**. Oncotarget.** 2014 Oct 30;5(20):9619-25. PMID: 25294813. **IF 5.168**
63. Vicari L, Martinetti D, Buccheri S, Colarossi C, Aiello E, Stagno F, Villari L, Cavalli M, Di Raimondo F, Gulisano M, De Maria R, Vigneri P. Increased phospho-mTOR expression in megakaryocytic cells derived from CD34+ progenitors of essential thrombocythaemia and myelofibrosis patients. **Br J Haematol**. 2012 Oct;159(2):237-40. **IF 5.128**
64. Nabissi M, Morelli MB, Amantini C, Farfariello V, Ricci-Vitiani L, Caprodossi S, Arcella A, Santoni M, Giangaspero F, De Maria R, Santoni G. TRPV2 channel negatively controls glioma cell proliferation and resistance to Fas-induced apoptosis in ERK-dependent manner. **Carcinogenesis**. 2010 Mag; 31(5):794-803. **IF 5.072**

IMPACT FACTOR < 5

1. De Nicola F, et al. Deep sequencing and pathway-focused analysis revealed multigene oncodriver signatures predicting survival outcomes in advanced colorectal cancer. **Oncogenesis**. 2018 Jul 22;7(7):55 **IF 4.722**
2. Villanova L. et al. Micro-Economics of Apoptosis in Cancer: ncRNAs Modulation of BCL-2 Family Members. **Int J Mol Sci**. 2018 Mar 23;19(4) **IF 3.687**
3. Ciuffreda L, Di Sanza C, Cesta Incani U, Eramo A, Desideri M, Biagioni F, Passeri D, Falcone I, Sette G, Bergamo P, Anichini A, Sabapathy K,McCubrey JA, Ricciardi MR, Tafuri A, Blandino G, Orlandi A, De Maria R, Cognetti F, Del Bufalo D, Milella M. The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. **J Mol Med** (Berl). 2012 Jun;90(6):667-79. **IF 4.938**
4. Ricci-Vitiani L, Fabrizi E, Palio E, De Maria R. Colon Cancer stem cells. **J Mol Med.** 2009 Nov; 87(11):1097-1104. **IF 4.938**
5. Ciceroni C, Arcella A, Mosillo P, Battaglia G, Mastrantoni E, Oliva MA, Carpinelli G, Santoro F, Sale P, Ricci-Vitiani L, De Maria R, Pallini R, Giangaspero F, Nicoletti F, Melchiorri D. Type-3 metabotropic glutamate receptors negatively modulate bone morphogenetic protein receptor signaling and support the tumourigenic potential of glioma-initiating cells. **Neuropharmacology**. 2008 Sep; 55(4):568-576. **IF 4.249**
6. Ricci-Vitiani L, Runci D, D'Alessandris QG, Cenci T, Martini M, Bianchi F, Maira G, Stancato L, De Maria R, Larocca LM, Pallini R. Chemotherapy of skull base chordoma tailored on responsiveness of patient-derived tumor cells to rapamycin. **Neoplasia**. 2013 Jul;15(7):773-82. **IF 4.994**
7. Montano N, Cenci T, Martini M, D'Alessandris QG, Pelacchi F, Ricci-Vitiani L, Maira G, De Maria R, Larocca LM, Pallini R Expression of EGFRvIII in glioblastoma: prognostic significance revisited. **Neoplasia**. 2011 Dec;13(12):1113-21 **IF 4.994**
8. Melucci E, et al. Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-linechemotherapy. **J Transl Med**. 2018 Feb 5;16(1):22. **IF 3.786**
9. Colace L, Boccia S, De Maria R, Zeuner A. Colorectal cancer: towards new challenges and concepts of preventive healthcare. **Ecancermedicalscience**. 2017 Nov 28;11:ed74. **IF N/A**
10. De Angelis ML, De Maria R, Baiocchi M. How to Assess Drug Resistance in Cancer Stem Cells. Methods Mol Biol. 2018;1692:107-115. **IF N/A**
11. Di Benedetto A, et al. Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression. Sci Rep. 2017 Aug 14;7(1):8078. **IF 4.122**
12. Lucchetti D, et al. Differentiation Affects the Release of Exosomes from Colon Cancer Cells and Their Ability to Modulate the Behavior of Recipient Cells. **Am J Pathol**. 2017 Jul;187(7):1633-1647. **IF 4.206**
13. Pizzuti L, et al. GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer. **J Cell Physiol**. 2018 Feb;233(2):1396-1401. **IF 4.080**
14. Ercolani C, et al. Expression of phosphorylated Hippo pathway kinases (MST1/2 and LATS1/2) in HER2-positive and triple-negative breast cancer patients treated with neoadjuvant therapy. **Cancer Biol Ther**. 2017 May 4;18(5):339-346. **IF 3.373**
15. Milella M, et al. PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. **Sci Rep**. 2017 Feb 21;7:43013. **IF 4.122**
16. Barba M, et al. Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer. **BMC Cancer**. 2017 Feb 6;17(1):101. **IF 3.288**
17. Di Benedetto A, et al. Association between AXL, Hippo Transducers, and Survival Outcomes in Male Breast Cancer. **J Cell Physiol**. 2017 Aug;232(8):2246-2252. **IF 4.080**
18. Di Benedetto A, et al. HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes. **Sci Rep**. 2016 Oct 7;6:35121. **IF 4.122**
19. Bonci D, De Maria R. miR-15/miR-16 loss, miR-21 upregulation, or deregulation of their target genes predicts poor prognosis in prostate cancer patients. Mol Cell Oncol. 2015 Dec 10;3(4):e1109744. **IF**
20. Maugeri-Saccà M, et al. Presurgical window of opportunity trial design as a platform for testing anticancer drugs: Pros, cons and a focus on breast cancer. **Crit Rev Oncol Hematol**. 2016 Oct;106:132-42. **IF 4.495**
21. Vici P, et al Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. **Expert Rev Vaccines** 2016 10; 15: 1327-36. **IF 4.271**
22. Marziali G, et al. Metabolic/Proteomic Signature Defines Two Glioblastoma Subtypes With Different Clinical Outcome. **Sci Rep-UK** 2016 Feb; 6: 21557 **IF 4.122**
23. Busco S, et al. Italian cancer figures - Report 2015: The burden of rare cancers in Italy. **Epidemiol Prev** 2016 Jan-Feb; 40: 1-120 **IF 1.289**

24. Palombo F, De Paoli P, De Maria R. Alleanza Contro il Cancro: the accreditation system of the Excellence Network of Italian Cancer Centers in the precision medicine era. **Tumori**. 2015;101 Suppl 1:S64-6. **IF 1.233**
25. Canitano S, et al. The Regina Elena National Cancer Institute process of accreditation according to the standards of the Organisation of European Cancer Institutes. **Tumori**. 2015;101 Suppl 1:S51-4. . **IF 1.233**
26. Paradiso A, Belardelli F, De Paoli P, De Maria R. International Accreditation of Cancer Centres of Italian Network of Alleanza contro il Cancro: introductory remarks. **Tumori**. 2015;101 Suppl 1:1. . **IF 1.233**
27. De Angelis ML, et al. Cancer Stem Cell-Based Models of Colorectal Cancer Reveal Molecular Determinants of Therapy Resistance. **Stem Cells Transl Med**. 2016 Apr;5(4):511-23. **IF 4.000**
28. Vici P, et al. DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis. **PLoS One**. 2016 Mar 1;11(3):e0149872. **IF 2.806**
29. Bonci D, De Maria R. A predictive signature for therapy assignment and risk assessment in prostate cancer. **Oncoscience**. 2015 Nov 20;2(11):920-3. **IF N/A**
30. De Paoli P, et al. Alliance Against Cancer, the network of Italian cancer centers bridging research and care. **J Transl Med**. 2015 Nov 14;13:360. **IF 3.786**
31. Vitale I, Manic G, Dandrea V, De Maria R. Role of autophagy in the maintenance and function of cancer stem cells**. Int J Dev Biol.** 2015;59(1-3):95-108. **IF 1.785**
32. Maugeri-Saccà M, et al. The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications. **Expert Rev Mol Med**. 2015 Jul 2;17:e14. **IF 4.405**
33. Tabolacci C, et al. Aloe-emodin exerts a potent anticancer and immunomodulatory activity on BRAF-mutated human melanoma cells. **Eur J Pharmacol**. 2015 Sep 5;762:283-92. **IF 2.896**
34. Iannolo G, et al. Numb Expression Contributes to the Maintenance of an Undifferentiated State in Human Epidermis. **Cell Transplant**. 2016;25(2):353-64. **IF 3.006**
35. Tate CM, et al. A BMP7 Variant Inhibits Tumor Angiogenesis In Vitro and In Vivo through Direct Modulation of Endothelial Cell Biology. **PLoS One**. 2015 Apr 28;10(4):e0125697. **IF 2.806**
36. Rosi A, et al. (1) H NMR spectroscopy of glioblastoma stem-like cells identifies alpha-aminoadipate as a marker of tumor aggressiveness. **NMR Biomed.** 2015 Mar;28(3):317-26. **IF 3.044**
37. Maugeri-Saccà M, et al. Cancer stem cells: are they responsible for treatment failure? **Future Oncol**. 2014 Oct;10(13):2033-44. **IF 2.131**
38. Cannistraci A, Di Pace AL, De Maria R, Bonci D. MicroRNA as new tools for prostate cancer risk assessment and therapeutic intervention: results from clinical data set and patients' samples. **Biomed Res Int**. 2014;2014:146170. **IF 2.476**
39. Di Lauro L, et al. Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series. **Breast Cancer Res Treat**. 2014 Nov;148(1):73-80. **IF 3.940**
40. Maugeri-Saccà M, et al. Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations. **Breast Cancer Res Treat**. 2014 Sep;147(2):227-35. **IF 3.940**
41. Maccalli C, De Maria R. Cancer stem cells: perspectives for therapeutic targeting. **Cancer Immunol Immunother**. 2015 Jan;64(1):91-7. **IF 4.846**
42. Pelosi A, et al. Dual promoter usage as regulatory mechanism of let-7c expression in leukemic and solid tumors. **Mol Cancer Res**. 2014 Jun;12(6):878-89. **IF 4.974**
43. Deriu PL, et al. Accreditation for excellence of cancer research institutes: recommendations from the Italian Network of Comprehensive Cancer Centers. **Tumori**. 2013 Nov-Dec;99(6):293e-8e. **IF 1.233**
44. Forte S, et al. Gene expression analysis of PTEN positive glioblastoma stem cells identifies DUB3 and Wee1 modulation in a cell differentiation model. **PLoS One**. 2013 Dec 12;8(12):e81432. **IF 2.806**
45. Guidoni L, et al. 1H NMR detects different metabolic profiles in glioblastoma stem-like cells. **NMR Biomed**. 2014 Feb;27(2):129-45. **IF 3.044**
46. Maugeri-Sacca M, et al. Approaching the increasing complexity of non-small cell lung cancer taxonomy. **Curr Pharm Des**. 2014;20(24):3973-81. **IF 2.611**
47. Vari S, et al. Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. **Expert Opin Drug Discov**. 2013 Nov;8(11):1381-97. **IF 3.846**
48. Salerno M, et al. Sphere-forming cell subsets with cancer stem cell properties in human musculoskeletal sarcomas. **Int J Oncol**. 2013 Jul;43(1):95-102. **IF 3.076**
49. Federici G, et al. 3rd. Systems analysis of the NCI-60 cancer cell lines by alignment of protein pathway activation modules with "-OMIC" data fields and therapeutic response signatures. **Mol Cancer Res**. 2013 Jun;11(6):676-85. **IF 4.597**
50. Maugeri-Sacca M, Coppola V, De Maria R, Bonci D. Functional role of microRNAs in prostate cancer and therapeutic opportunities. **Crit Rev Oncog**. 2013;184):303-15. **IF N/A**
51. Maugeri-Saccà M, Di Martino S, De Maria R. Biological and clinical implications of cancer stem cells in primary brain tumors. **Front Oncol**. 2013 Jan 25;3:6. **IF 4.416**

52. Sette G, et al. EGFR inhibition abrogates leiomyosarcoma cell chemoresistance through inactivation of survival pathways and impairment of CSC potential. **PLoS One**. 2012;7(10):e46891. **IF 2.806**
53. Silvestri A, et al. Protein pathway activation mapping of colorectal metastatic progression reveals metastasis-specific network alterations. **Clin Exp Metastasis**. 2013 Mar;30(3):309-16. **IF 3.144**
54. Maugeri-Saccà M, Coppola V, Bonci D, De Maria R. MicroRNAs and prostate cancer: from preclinical research to translational oncology. **Cancer J.** 2012 May-Jun;18(3):253-61. **IF 3.662**
55. Ciuffreda L, et al. The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. **J Mol Med** (Berl). 2012 Jun;90(6):667-79. **IF 4.686**
56. Low J, et al. Knockdown of ubiquitin ligases in glioblastoma cancer stem cells leads to cell death and differentiation. **J Biomol Screen**. 2012 Feb;17(2):152-62. **IF 2.444**
57. Tafani M, et al. Pro-inflammatory gene expression in solid glioblastoma microenvironment and in hypoxic stem cells from human glioblastoma. **J Neuroinflammation**. 2011 Apr 13;8:32. **IF 4.351**
58. Maugeri-Saccà M, De Maria R. Translating basic research in cancer patient care. **Ann Ist Super Sanita**. 2011;47(1):64-71. **IF 0.773**
59. Maugeri-Saccà M, Zeuner A, De Maria R. Therapeutic targeting of cancer stem cells. **Front Oncol.** 2011 Jun 17;1:10. **IF 4.416**
60. Accordi B, et al. Functional protein network activation mapping reveals new potential molecular drug targets for poor prognosis pediatric BCP-ALL. **PLoS One**. 2010 Oct 21;5(10):e13552. **IF 2.806**
61. Conticello C, et al. NF-κB localization in multiple myeloma plasma cells and mesenchymal cells. **Leuk Res.** 2011 Jan;35(1):52-60. **IF 2.351**
62. Low J, et al. Knockdown of cancer testis antigens modulates neural stem cell marker expression in glioblastoma tumor stem cells. **J Biomol Screen**. 2010 Aug;15(7):830-9. **IF 2.444**
63. Calzolari A, et al. Transferrin receptor 2 is frequently and highly expressed in glioblastomas. **Transl Oncol**. 2010 Apr;3(2):123-34. **IF 3.071**
64. Mollinari C, et al. Downregulation of thymosin beta4 in neural progenitor grafts promotes spinal cord regeneration. **J Cell Sci.** 2009 Nov 15;122(Pt 22):4195-207. **IF 4.431**
65. Ricci-Vitiani L, Fabrizi E, Palio E, De Maria R. Colon cancer stem cells. **J Mol Med (Berl).** 2009 Nov;87(11):1097-104. **IF 4.686**
66. Mercatelli N, et al. The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. **PLoS One**. 2008;3(12):e4029. **IF 2.806**
67. Adjaye JA, et al. Pluripotency and differentiation in embryos and stem cells. **Int J Dev Biol**. 2008;52(7):801-9. **IF 1.785**
68. Conticello C, et al. Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia. **Acta Haematol**. 2008;120(1):19-30. **IF 1.285**
69. Vicari L, et al. Paclitaxel loading in PLGA nanospheres affected the in vitro drug cell accumulation and antiproliferative activity. **BMC Cancer**. 2008 Jul 25;8:212. **IF 3.288**
70. Salvioli R, Ricci-Vitiani L, Tatti M, Scarpa S, De Maria R, Vaccaro AM. The secretion and maturation of prosaposin and procathepsin D are blocked in embryonic neural progenitor cells. **Biochim Biophys Acta**. 2008 Aug;1783(8):1480-9. **IF 3.679**
71. Iannolo G, Conticello C, Memeo L, De Maria R. Apoptosis in normal and cancer stem cells. **Crit Rev Oncol Hematol**. 2008 Apr;66(1):42-51. **IF 4.495**
72. Ricci-Vitiani L, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007 Jan 4;445(7123):111-5.
73. Ricci-Vitiani L, et al. Establishing tumor cell lines from aggressive telomerase-positive chordomas of the skull base. Technical note. **J Neurosurg**. 2006 Sep;105(3):482-4. **IF 4.069**
74. Ricci-Vitiani L, et al. Influence of local environment on the differentiation of neural stem cells engrafted onto the injured spinal cord. **Neurol Res**. 2006 Jul;28(5):488-92. **IF 1.376**
75. Felli N, et al. Multiple members of the TNF superfamily contribute to IFN-gamma-mediated inhibition of erythropoiesis. **J Immunol**. 2005 Aug 1;175(3):1464-72. **IF 4.920**
76. Eramo A, et al. CD95 death-inducing signaling complex formation and internalization occur in lipid rafts of type I and type II cells. **Eur J Immunol**. 2004 Jul;34(7):1930-40. **IF 4.227**
77. Conticello C, et al. IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins. **J Immunol**. 2004 May 1;172(9):5467-77. **IF 4.920**
78. Stassi G, Zeuner A, Di Liberto D, Todaro M, Ricci-Vitiani L, De Maria R. Fas-FasL in Hashimoto's thyroiditis. **J Clin Immunol**. 2001 Jan;21(1):19-23. **IF 3.382**
79. Ricci-Vitiani L, Conticello C, Zeuner A, De Maria R. CD95/CD95L interactions and their role in autoimmunity. **Apoptosis**. 2000 Nov;5(5):419-24. **IF 3.833**

80. Stassi G, et al. Involvement of Fas/FasL system in the pathogenesis of autoimmune diseases and Wilson's disease. **Arch Immunol Ther Exp** (Warsz). 1999;47(3):129-33. **IF 3.018**
81. De Maria R, Palmieri G, Santoni A. Induction of Ca2+ flux by adhesion molecules in lymphocytes. **Methods Mol Biol**. 1999;96:199-204. Review. **IF N/A**
82. Malisan F, Rippo MR, De Maria R, Testi R. Lipid and glycolipid mediators in CD95-induced apoptotic signaling. **Results Probl Cell Differ**. 1999;23:65-76. **IF N/A**
83. Stassi G, et al. Fas/Fas ligand-driven T cell apoptosis as a consequence of ineffective thyroid immunoprivilege in Hashimoto's thyroiditis. **J Immunol**. 1999 Jan 1;162(1):263-7. **IF 4.920**
84. Stassi G, et al. Defective expression of CD95 (FAS/APO-1) molecule suggests apoptosis impairment of T and B cells in HLA-B8, DR3-positive individuals. **Hum Immunol**. 1997 Jun;55(1):39-45. PubMed PMID: 9328788. **IF 2.311**
85. De Luca A, et al. Fas-induced changes in cdc2 and cdk2 kinase activity are not sufficient for triggering apoptosis in HUT-78 cells. **J Cell Biochem**. 1997 Mar 15;64(4):579-85. **IF 3.466**
86. Cascino I, Papoff G, De Maria R, Testi R, Ruberti G. Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. **J Immunol.** 1996 Jan 1;156(1):13-7. **IF 4.920**
87. Palmieri G, et al. Cross-linking of alpha 4 beta 1 and alpha 5 beta 1 fibronectin receptors enhances natural killer cell cytotoxic activity. **J Immunol**. 1995 Dec 1;155(11):5314-22. **IF4.920**
88. Candore G, et al. T-cell activation in HLA-B8, DR3-positive individuals. Early antigen expression defect in vitro. **Hum Immunol**. 1995 Apr;42(4):289-94. **IF 2.311**
89. Galandrini R, De Maria R, Piccoli M, Frati L, Santoni A. CD44 triggering enhances human NK cell cytotoxic functions. **J Immunol**. 1994 Nov 15;153(10):4399-407. **IF 4.920**
90. De Maria R, et al. Defective T cell receptor/CD3 complex signaling in human type I diabetes. **Eur J Immunol.** 1994 Apr;24(4):999-1002. **IF 4.227**
91. Giordano C, et al. Autofluorescence-activated sorting of human single beta cells and endocrine non-beta cells after enzymatic islet dissociation. **Transplant Proc**. 1994 Apr;26(2):651-2. **IF 0.806**
92. De Maria R, et al. Continuous in vivo activation and transient hyporesponsiveness to TcR/CD3 triggering of human gut lamina propria lymphocytes. **Eur J Immunol.** 1993 Dec;23(12):3104-8. **IF4.227**
93. Giordano C, et al. Study of T-cell activation in type I diabetic patients and pre-type I diabetic subjects by cytometric analysis: antigen expression defect in vitro. **J Clin Immunol**. 1993 Jan;13(1):68-78. **IF 3.382**
94. Giordano et al. Analysis of T-lymphocyte subsets after phytohemagglutinin stimulation in normal and type 1 diabetic mothers and their infants. **Am J Reprod Immunol**. 1992 Sep;28(2):65-70. **IF 2.916**